937-38-2

Usage

Uses

Used in Illicit Drug Production:
1-Chloro-3-Phenylacetone is used as a precursor chemical for the synthesis of illegal drugs, specifically methamphetamine and MDMA. Its role in the production of these substances has led to its classification as a controlled substance in many countries, with strict regulations on its production, distribution, and use. 1-Chloro-3-Phenylacetone's association with the illegal drug trade has overshadowed any potential legitimate applications it may have.

InChI:InChI=1/C9H9ClO/c10-7-9(11)6-8-4-2-1-3-5-8/h1-5H,6-7H2

Upstream product

• 186581-53-3 diazomethane 
• 60-29-7 diethyl ether 
• 103-80-0 phenylacetyl chloride 
• 95547-16-3 1-Phenyl-3-(trimethylsilyl)propan-2-one 
• 74-97-5 chlorobromomethane 
• 101-97-3 Ethyl 2-phenylethanoate 
• 79-04-9 chloroacetyl chloride 
• 6921-34-2 benzylmagnesium chloride 
• 20485-53-4 1-chloro-3-diazopropan-2-one 
• 71-43-2 benzene 
• 5396-65-6 1-chloro-3-phenylpropan-2-ol 
• 7647-01-0 hydrogenchloride 
• 858843-32-0 4-phenoxy-2-phenyl-acetoacetic acid methyl ester 
• 4250-02-6 1-diazo-3-phenyl-2-propanone 

Downstream Products

• 103-25-3 3-phenylpropanoic acid methyl ester 
• 86521-18-8 3-Ethylthio-1-phenyl-2-propanone 
• 36960-03-9 2-oxo-3-phenylpropyl acetate 
• 726-26-1 phenyl 3-phenylpropanoate 
• 27839-94-7 1-phenyl-3-(phenylsulfonyl)propan-2-one 
• 4982-08-5 1-hydroxy-3-phenylpropan-2-one 
• 121426-36-6 2,5-dibenzyl-[1,4]dithiane-2,5-diol 
• 7496-56-2 2-amino-4-benzylthiazole 
• 94378-12-8 N-[1-(4-benzyl-thiazol-2-yl)-ethyl]-benzamide 
• 92102-02-8 Thiophosphorsaeure- 
• 91338-87-3 Dithiophosphorsaeure- 
• 59502-86-2 (2,4-dibenzyl-2,5-dihydro-oxazol-2-yl)-methanol 
• 66542-68-5 1-phenyl-3-thiocyanatopropan-2-one 
• 4458-19-9 2-Chloromethyl-1-phenyl-but-3-yn-2-ol 

Relevant academic research and scientific papers

Photoenzymatic Synthesis of α-Tertiary Amines by Engineered Flavin-Dependent "ene"-Reductases

α-Tertiary amines are a common motif in pharmaceutically important molecules but are challenging to prepare using asymmetric catalysis. Here, we demonstrate engineered flavin-dependent ‘ene'-reductases (EREDs) can catalyze radical additions into oximes to prepare this motif. Two different EREDs were evolved into competent catalysts for this transformation with high levels of stereoselectivity. Mechanistic studies indicate that the oxime contributes to the enzyme templated charge-transfer complex formed between the substrate and cofactor. These products can be further derivatized to prepare a variety of motifs, highlighting the versatility of ERED photoenzymatic catalysis for organic synthesis.

Facile and efficient preparation of α-halomethyl ketones from α-diazo ketones catalyzed by iron(III) halides and silica gel

An efficient and mild method for the synthesis of α-halomethyl ketones from α-diazo ketones was developed using ferric chloride or bromide as the halogen source and silica gel as the hydrogen source, with good to excellent yields.

A Simple and Efficient Method for the Preparation of α-Halogenated Ketones Using Iron(III) Chloride and Iron(III) Bromide as Halogen Sources with Phenyliodonium Diacetate as Oxidant

α-Halogenated ketones are both unique structure moieties existing in biologically natural products and valuable synthetic intermediates for the preparation of functional molecules. An efficient and scalable method for the preparation of α-halogenated ketone using iron (III) chloride and iron (III) bromide as halogen sources with phenyliodonium diacetate as oxidant has been developed, featuring mild reaction conditions, environmentally friendly reagents, and wide substrate scope. Notably, the three-step synthesis of drug prasugrel was achieved using this developed method as a key step with 30% yield on gram-scale. Additionally, the reaction mechanism involving chloride cation was proposed based on some preliminary control experiments. (Figure presented.).

Homologation of isocyanates with lithium carbenoids: A straightforward access to α-halomethyl- and α,α-dihalomethylamides

Treatment of widely available isocyanates with monohalolithium and dihalolithium carbenoids provides a valuable protocol for the one-pot preparation of α-halo- and α,α-dihaloacetamide derivatives. While monohalolithium carbenoids can be prepared by a smoo

Continuous flow generation and reactions of anhydrous diazomethane using a teflon AF-2400 tube-in-tube reactor

A continuous process for generation, separation, and reactions of anhydrous diazomethane in a tube-in-tube reactor was developed. The inner tube of the reactor is made of hydrophobic, gas-permeable Teflon AF-2400. The diazomethane is formed in the inner tube and then diffuses through the permeable membrane into the outer chamber and subsequently reacts in the solution carried within. This technique allows safe and scalable reactions with dry diazomethane to be performed on a laboratory scale.

Addition of lithium carbenoids to isocyanates: A direct access to synthetically useful N-substituted 2-haloacetamides

The addition of lithium carbenoids to isocyanates provides a versatile access to N-substituted 2-haloacetamides: the reaction tolerates the presence of variously functionalized substituents on the nitrogen atom, including sterically demanding ones and reactive halogens. No erosion of the enantiopurity was observed in the case of optically active isocyanates. One of the substrates prepared has been employed in Charette's type chemoselective addition of a Grignard reagent to access an α-chloroketone.

β-fluoroamphetamines via the stereoselective synthesis of benzylic fluorides

A range of substituted aryl epoxides undergo efficient ring-opening hydrofluorination upon treatment with 0.33 equiv of BF3-OEt 2 in CH2Cl2 at -20 -°C to give the corresponding syn-fluorohydrins, consistent with a mechanism involving a stereoselective SN1-type epoxide ring-opening process. The benzylic fluoride products of these reactions are valuable templates for further elaboration, as demonstrated by the preparation of a range of aryl-substituted β-fluoroamphetamines.

Methods and Compositions for Treatment of Scleritis and Related Disorders

The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W1, W2, R1, L, X, Y, Z, and n1 are defined as described herein.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

Methods and compositions for selectin inhibition

The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.